Also known as: RVO
Retinal vein occlusion is a vascular eye disease caused by blockage of retinal venous outflow, leading to retinal hemorrhage, edema, and vision loss. Major subtypes are branch and central retinal vein occlusion.
The FDA approved updated labeling for Vabysmo to allow extended treatment of macular edema following retinal vein occlusion beyond six months. The label update removes the prior 6-month restriction and retains monthly 6 mg intravitreal dosing.
The FDA approved an updated Vabysmo label for macular edema following retinal vein occlusion beyond six months. The decision extends treatment based on data showing visual acuity gains and central subfield thickness reductions maintained through week 72.
Zydus Lifesciences plans to launch Semaglutide injection in India after patent expiry and introduced ANYRA, India's first indigenous Aflibercept biosimilar. The USFDA cleared the company's Ahmedabad injectable facility with zero observations.
The FDA has approved an expanded label for Sandoz's aflibercept biosimilar Enzeevu to include multiple retinal indications beyond its original approval for neovascular age-related macular degeneration. The product is expected to launch in the US in Q4 2026.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07718503 |
A Study on the Combination of Tongluo Huayu Formula in Treating RVO of Phlegm-Stasis Intertwinement Type: Based on the Mechanism of Systemic Metabolic Regulation Mediated by Gut Microbiota |
NOT_YET_RECRUITING | NA |
| NCT07501052 |
Study of the SCD411 Prefilled Syringe for Treating Adults With Wet Age-Related Macular Degeneration, Retinal Vein Occlusion, Diabetic Macular Edema, or Diabetic Retinopathy |
COMPLETED | PHASE2 |
| NCT07318428 |
AI-Assisted Detection of Posterior Segment Diseases: DR, AMD, RVO, and Glaucoma |
COMPLETED | NA |
| NCT06439576 |
Real World Evidence in China: Faricimab Use in Diabetic Macular Edema, Retinal Vein Occlusion, and Neovascular Age-Related Macular Degeneration (The Farseeing Study) |
ACTIVE_NOT_RECRUITING | |
| NCT05476926 |
A Real-World Study to Gain Clinical Insights Into Roche Ophthalmology Products |
ACTIVE_NOT_RECRUITING | |
| NCT04847869 |
Near-Infrared Light Photobiomodulation Treatment for Retinal Vein Occlusion Macular Oedema |
TERMINATED | NA |
| NCT04505618 |
Optical Coherence Tomography Angiography in Subjects With Retinal Vascular Disease |
RECRUITING | NA |
| NCT03680794 |
Soluble Cluster of Differentiation 160 (sCD160) in Sera and Intra-ocular Fluids: Association With Ischaemic Retinopathies |
RECRUITING | NA |
| NCT01496625 |
National Eye Institute Biorepository for Retinal Diseases |
RECRUITING |
